PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Kronberg]

Who knows Tomix perhaps you are right. Although in the long run I believe Protalix will be OK.If you listened the CC perhaps you noticed the following statement.

"The decision to engage with the agency is also in light of the recent FDA designation of Fabry disease condition with a significant unmet need coupled with the fact there is currently no available therapy with final approval in the U.S. were the two commercial available therapies were approved on accelerated temporary basis with [indiscernible] market only where we believe our data set was minimum."

So this is a huge chance IMO for PRX-102 clearance in 2019 and the company has money for this period.And secondly, the top management has recently received a significant salary increases.M.Manor' pay is $834.35k at present (more recently, it was ~$434k).https://finance.yahoo.com/quote/PLX/profile?p=PLX
I do not think that they could get significant salary increases, plus ~ 4m options recently if things went badly in the company.